Atorvastatin

NEW ORLEANS — In the STOP-CA trial, prophylactic atorvastatin therapy reduced the occurrence of anthracycline-associated left ventricular dysfunction at 12 months among patients who underwent treatment for Hodgkin and non-Hodgkin lymphoma.

Compared with atorvastatin, rosuvastatin shows higher risks of hematuria, proteinuria and kidney failure in patients with chronic kidney disease.

Compared with atorvastatin, rosuvastatin is associated with increased risks of hematuria, proteinuria and kidney failure with replacement therapy, according to a study.

Although lipid-lowering medications are generally well tolerated, rare complications can include statin-associated autoimmune myopathy and drug-induced acute pancreatitis, a speaker reported.

Once-daily atorvastatin 40 mg fails to significantly reduce cartilage loss over 2 years in patients with symptomatic knee osteoarthritis, compared with placebo, according to data published in Arthritis & Rheumatology.

Atorvastatin 20 mg daily vs. placebo in patients who had reported muscle-related side effects from statins.

Triple combination therapy with bempedoic acid, ezetimibe and atorvastatin significantly reduced LDL among patients with hypercholesterolemia, researchers reported.

Atorvastatin demonstrated no overall effect on the frequency or severity of muscle symptoms among individuals who previously reported severe muscle symptoms while on statins, compared with placebo, according to data published in The BMJ.

Statins and placebo triggering symptoms in patients with past statin intolerance.

Patients who developed symptoms within 2 weeks of statin initiation reported similar side effects while on placebo, suggesting a large proportion of burden owed to the nocebo effect, according to findings from the SAMSON trial.